A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants With Late-Onset Pompe Disease
Abroad (travel likely)RecruitingPHASE1
Conditions
Late-onset Pompe Disease
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University of California-Irvine, Irvine, California, United States
Duke University School of Medicine - Early Phase Research Unit, Durham, North Carolina, United States
The Lysosomal & Rare Disorders Research & Treatment Center, Fairfax, Virginia, United States
Study leads
Medical Monitor
Study Director
Denali Therapeutics Inc.